Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
It is very uncertain whether scheduled PDE5I changes serious adverse events compared with on demand PDE5I (very low certainty).
Scheduled PDE5I may leads to lower serious adverse events compared with on demand placebo or no treatment (low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
Exercise showed no clear difference in serious adverse events compared with no exercise (low certainty).
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).